Abstract
Thirty patients with psoriasis or other nonmalignant diseases had liver biopsies done before treatment with low-dose methotrexate, 15 mg/week, and then at one-to two-year intervals as long as they continued the methotrexate. All patients were symptomaticaly improved on this regimen. The 15 patients who had normal liver biopsies at the start of the study had normal biopsies after methotrexate. Fifteen others had minor hepatic histologic abnormalities before treatment. Eleven patients had fatty infiltration. Ten showed no significant change after treatment while one had increased fat and portal fibrosis on a fourth liver biopsy done seven years after MTX was begun. This last patient, a former alcohol abuser, continued methotreaxte and showed no further worsening at 8 years. The remaining four had portal fibrosis before treatment. One patient had less fibrosis after methotrexate, two patients slightly more fibrosis, and one a marked increase in portal fibrosis. No patient developed cirrhosis or clinical liver disease. Our results suggest that in the absence of alcohol consumption, low-dose weekly methotrexate treatment rarely causes clinically significannt liver damage.
Similar content being viewed by others
References
Hersh EM, Wong VG, Henderson ES, Freirich EJ: Hepatotoxic effects of methotrexate. Cancer 19:600–606, 1966
Tobias H, Auerbach R: Hepatotoxicity of long term methotrexate therapy for psoriasis Arch Intern Med 132:391–396, 1973
Weinstein GD, Cox JW, Suringa DWR, Millard MM, Kalser M, Frost P: Evaluation of possible chronic hepatotoxicity from methotrexate for psoriasis. Arch Dermatol 102:613–618, 1970
Roenigk HH, Bergfeld WF, St. Jacques R, Owens FJ, hawk WA: Hepatotoxicity of methotrexate in the treatment of psorisis. Arch Dermatol 103:251–261, 1971
Dahl GC, Gregory MM, Scheuer PJ: Liver damage due to methotrexate in patients with psoriasis. Br Med J 1:625–630, 1971
Warin AP, Landells JW: Levene GM, Baker H: A prospective study of the effects of weekly oral methotrexate on liver biopsy. Br J Dermatol 93:321–327, 1975
Nyfors A, Poulsen H: Liver biopsies from psoriatis related to methotrexate therapy. Acta Path Microbiol Scand, Sect A 84:262–270, 1976
Zachariae H, Kragballe K, Sogaard H: Methotrexate induced liver cirrhosis. Br J Dermatol 102:407–512, 1980
Robinson J, Baughman RD, Auerbach R, Cimis RJ: Methotrexate hepatitoxicity in psoriasis. Arch Dermatol 116:413–415, 1980
Delmonte L, Jukes TH: Folic acid antagonists in cancer chemotherapy. Pharm Rev 14:91–135, 1962
Coe RO, Bull FE: Cirrhosis associated with methotrexate treatment of psoriasis. JAMA 206:1515–1520, 1968
Berlin NI: Folic acid antagonists. Effects on the cell and the patient. Ann Intern Med 59:931–956, 1963
O'Rourke RA, Eckert GE: Methotrexat-induced hepatic injury in an adult. Arch Intern Med 113:191–194, 1964
Muller SA, Farrow GM, Martalock DL: Cirrhosis caused by methotrexate in the treatment of psoriasis. Arch Dermatol 100:523–530, 1969
Epstein EG Jr, Craft JD Jr: Cirrhosis following methotrexate administration for psoriasis. Arch Dermatol 100:531–534, 1969
Berge G, Lundquist A, Rorsman H, Akerman M: Liver biopsy in psoriasis. Br J Dermatol 82:250–253, 1970
Shapiro HA, Trowbridge JO, Lee JC, Akerman M: Liver disease in psoriatics-an effect of methotrexate therapy. Arch Dermatol 110:547–551, 1974
Author information
Authors and Affiliations
Additional information
Supported in part by NIH Research Training Grant AM 07024, Clinical Study Unit Grant RR 300054, and a Fellowship from the Jack Zomlefer Fund.
Rights and permissions
About this article
Cite this article
Lanse, S.B., Arnold, G.L., Gowans, J.D.C. et al. Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis. Digest Dis Sci 30, 104–109 (1985). https://doi.org/10.1007/BF01308193
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01308193